Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20234304 | 1.00 | APP (0.46) | APPEPHX2PLA2G4BL3MBTL1HDAC1 | |
| SCHEMBL20046548 | 0.99 | APP (0.47) | APPEPHX2 | |
| SCHEMBL20372774 | 0.97 | APP (0.49) | APPEPHX2PLA2G4BL3MBTL1 | |
| SCHEMBL20133425 | 0.92 | APP (0.55) | APPEPHX2 | |
| SCHEMBL18612221 | 0.92 | APP (0.55) | APPEPHX2 | |
| SCHEMBL20133273 | 0.92 | APP (0.55) | APPEPHX2 | |
| SCHEMBL24654312 | 0.88 | EPHX2 (0.42) | EPHX2PLA2G4BL3MBTL1HDAC1HDAC2 | |
| SCHEMBL18592225 | 0.88 | EPHX2 (0.42) | EPHX2PLA2G4BL3MBTL1HDAC1HDAC2 | |
| SCHEMBL18592223 | 0.88 | EPHX2 (0.42) | EPHX2PLA2G4BL3MBTL1HDAC1HDAC2 | |
| SCHEMBL22005873 | 0.87 | EPHX2 (0.41) | EPHX2PLA2G4BL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | APP 87/4885EPHX2 2978/4885PLA2G4B 3241/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | APP 551/4885EPHX2 1434/4885PLA2G4B 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.